Overview

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Status:
Terminated
Trial end date:
2016-05-03
Target enrollment:
Participant gender:
Summary
The CC-90003-ST -001 trial is a first-in-man, open-label study in subjects with locally-advanced or wide spread cancers to determine if CC-90003 (an oral medication) can be adequately tolerated with minimal side effects.
Phase:
Phase 1
Details
Lead Sponsor:
Celgene
Celgene Corporation